Pazufloxacin

Pazufloxacin is an orally active fluoroquinolone antimicrobial agent. Pazufloxacin inhibits DNA gyrase with IC₅₀ values of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa). Pazufloxacin exhibits broad-spectrum antimicrobial activity, with MIC₉₀ values ranging from 0.025 to 100 μg/mL against Gram-positive and Gram-negative bacteria, non-fermenting bacteria, Legionella spp., and anaerobic bacteria. Pazufloxacin is indicated for research on systemic infections, lung infections, urinary tract infections, and Legionella pneumonia^{[1][2][3][4][5]}. In Vitro:Pazufloxacin shows broad-spectrum antibacterial activity with MIC₉₀s ranging from 0.025 to 100 μg/mL against gram-positive bacteria, gram-negative bacteria, non-fermenters, Legionella spp., and anaerobes^[1].
Pazufloxacin inhibits DNA gyrase with IC₅₀s of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa)^[2].
In Vivo:Pazufloxacin (25 mg/kg; p.o.) shows good efficacy in mice with pulmonary infections, achieving 94% survival and eradication rates against Pseudomonas aeruginosa, which is greater than that of Ofloxacin (HY-B0125) and Norfloxacin (HY-B0132)^[1].
Pazufloxacin (5 mg/kg/day; i.p.; twice a day; 7 days) in combination with Sivelestat (HY-17443) reduces bacterial counts and inflammatory cells in the early phase of Legionella pneumonia in A/J mice, but does not significantly improve survival compared to monotherapy^[5].